Primary cutaneous lymphoma in Argentina: a report of a nationwide study of 416 patients. (7th October 2018)

• Record Type: Journal Article
• Authors: Abeldaño, Alejandra; Enz, Paula; Maskin, Matias; Cervini, Andrea B.; Torres, Natallia; Acosta, Ana C.; Narbaitz, Marina; Vanzulli, Silvia; Orentrajch, Mirta; Villareal, Marta A.; Garcia Pazos, Maria L.; Arias, Mariana; Zambrano Franco, Evelyn A.; Fontana, Maria I.; Chuit, Roberto
• Is Part Of: International journal of dermatology. Volume 58:Number 4(2019)
• Page Start: 449
• Page End: 455
• Publication Date: 2018-10-07
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/ijd.14262
• Languages: English
• ISSNs: 0011-9059

Abstract

Abstract: Background: The aim of this study was to determine the relative frequency of primary cutaneous lymphoma (PCL) in Argentina according to the new World Health Organization (WHO)‐European Organization for the Research and Treatment of Cancer (EORTC) classification system. Methods: A total of 416 patients from 21 dermatology services were included during a 5‐year period (2010–2015); these patients were classified using WHO‐EORTC criteria. Results: There were 231 (55.2%) males and 185 (44.8%) females; the male‐to‐female ratio was 1.35. The median age of the patients was 57 years (range, 0–90 years). Most patients were Caucasian (79%), and only 16% of patients were registered as Amerindian. Most patients (387/416, 93%) had cutaneous T‐cell lymphoma (CTCL); 28 patients (6.7%) were diagnosed with cutaneous B‐cell lymphoma (CBCL). The most frequent CTCL subtypes, in decreasing order of prevalence, were mycosis fungoides (MF), including its variants (75.7%); CD30+ primary cutaneous lymphoproliferative disorders (7.2%); and Sézary syndrome (SS) (3.1%). Cutaneous follicle center lymphoma was the most common CBCL subtype (2.9%). In the subset of patients ≤20 years of age, the most common condition was MF (57%), followed by extranodal NK‐T nasal‐type lymphoma (14%). Conclusions: This study revealed relatively higher rates of MF and lower rates of CBCL in Argentinean patients that have been reported in American and European countries.